Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00388180 · ClinicalTrials.gov registry record
An Exploratory Study To Look At The Effect Of Two Investigational Drugs On Body Fat And Inflammation
A clinical trial, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- 71
- Enrollment target
NCT00388180: Completed study, sponsored by GlaxoSmithKline.
NCT00388180 is a clinical trial that has completed, run by GlaxoSmithKline. The registered enrollment target is 71 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00388180 has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- 71 participants
- Enrollment target
Study Summary
The investigational drugs administered in this study activate proteins called PPARs. Data in the scientific literature on PPARs, as well as animal data and early clinical data generated by GSK with these drugs, suggest that activation of PPARs may cause the body to increase its use of fatty acids for energy, and lead to a reduction in body fat. There are also data to suggest a role for PPARs in regulating lipid (e.g., cholesterol) levels and inflammation. These and other activities of PPARs are being further explored in this clinical study.
Interventions
- DRUG GW501516
- DRUG GW590735
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 71 participants |
| Start Date | 2004-12 |
What the finished NCT00388180 record still lists
NCT00388180 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 71 participants, a relatively small participant target.
The record links to 0 conditions, and to 2 interventions - of which GW501516 is the first listed.
NCT00388180 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00388180 about?
NCT00388180 is a clinical study titled "An Exploratory Study To Look At The Effect Of Two Investigational Drugs On Body Fat And Inflammation". The investigational drugs administered in this study activate proteins called PPARs. Data in the scientific literature on PPARs, as well as animal data and early clinical data generated by GSK with these drugs, suggest that activation of PPARs may cause the body to increase its use of fatty acids fo...
What is the current status of trial NCT00388180?
This trial is currently completed. The enrollment target is 71 participants. The study started on 2004-12.
What interventions are being tested in trial NCT00388180?
The interventions under investigation include: GW501516 (DRUG), GW590735 (DRUG).
Who is sponsoring clinical trial NCT00388180?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05452889 · 71 participants · Early Phase 1
PET Image in PAH Patients
- NCT05766943 · 71 participants · NA
Reduction of Myopotential Interference With Smart Pass in S-ICD Patients
- NCT06229678 · 71 participants · Early Phase 1
Ketones, SGLT2, HFrEF
- NCT06377566 · 71 participants · Phase 2
A Study of BV-AVD in People With Bulky Hodgkin Lymphoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia